Recent developments in the pharmacotherapy of malignant melanoma

Abstract

The development of new targets for clinically successful treatments, such as pathways inhibitors and immune checkpoint antibodies, was made possible by analysing oncogenic signalling pathways and interactions. Although this is a step forward in the treatment of melanomas, these types of techniques faced a number of obstacles. The detailed characteristics of patients who will benefit from each technique will be used to develop biomarkers for the most effective treatment in advanced melanomas.